News Headlines
-
Evotec SE Appoints Dr Christian Wojczewski As Chief Executive Officer
4/23/2024
The Supervisory Board of Evotec SE has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer (“CEO”), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.
-
Amicus Therapeutics Inc And Almac Pharma Services Mark 15-Year Strategic Partnership With Patient Advocacy Event
4/22/2024
Almac Pharma Services, a member of the privately owned Almac Group providing innovative pharmaceutical development, manufacture and commercial services to global pharmaceutical and biotech organisations, has celebrated a key milestone of its strategic partnership with global biotechnology company, Amicus Therapeutics Inc, by hosting a patient advocacy event for its employees.
-
Ardena's Nanomedicines Facility Marks €20M Expansion With First GMP Approval
4/18/2024
Oss, The Netherlands: Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded nanomedicines facility.
-
ExoXpert Announces Agreement with Neucore Bio to Evaluate Advanced Exosome Loading
4/17/2024
ExoXpert, a Contract Development and Manufacturing Organization (CDMO) specializing in exosome production and a subsidiary of Exo Biologics, today announces a strategic partnership with Neucore Bio, a next-generation, non-viral engineered delivery technology company to leverage ExoXpert’s platform for evaluation of advanced exosome loading.
-
Imugene And Kincell Bio Announce Strategic Manufacturing And Process Development Partnership
4/16/2024
Imugene, Ltd. (“Imugene”)(ASX: IMU) and Kincell Bio, LLC (“Kincell”), announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice (CGMP) manufacturing facility and the transfer of process and analytical development activities to Kincell.
-
AmplifyBio And RNAV8 Bio Announce Strategic Partnership To Support mRNA Therapeutic Developers From Sequence Design To GMP Manufacture
4/16/2024
AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services that cover target optimization, preclinical safety studies, and manufacturing scale-up, and RNAV8 Bio, an emerging startup focused on mRNA engineering platforms, are partnering to provide a one-stop shop for the development of mRNA therapeutics.
-
BioHarvest Sciences Announces New Campus For Botanical Synthesis CDMO And Expansion Of Manufacturing Capacity
4/16/2024
BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) a biotechnology company pioneering its patented Botanical Synthesis technology process, today announced the signing of two agreements: a long term lease agreement for a new 80,000 square ft. facility in Yavne, Israel, and an equipment purchase agreement for 12 state of the art GMP clean rooms.
-
Medincell Enters Into Strategic Co-Development And Licensing Agreement With Abbvie To Develop Next-Generation Long-Acting Injectable Therapies
4/16/2024
Medincell today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications.
-
Curida, Small Molecules And Biologics CDMO, Secures Private Equity Investment From Signet Healthcare Partners
4/16/2024
Curida Holding AS (“Curida”) has announced a significant growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare private equity firm. This strategic partnership will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position.
-
Evergreen Theragnostics Completes $26M Capital Raise To Advance Novel Radiopharmaceutical Pipeline Into The Clinic, Prepare For First Commercial Product Launch, And Expand Industry-Leading CDMO Services
4/16/2024
Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT.